AstraZeneca's stock dropped on Friday following a decision by an FDA advisory panel to reject the company's experimental cancer drug, camizestrant.
The panel, which voted 6-3 against approval, expressed concerns over the drug's ability to demonstrate improved long-term survival rates in clinical trials for a specific type of breast cancer.
The rejection has led to a noticeable decline in the company's share price, reflecting investor disappointment over the setback in AstraZeneca's drug development pipeline.
The drug was intended to treat a type of breast cancer tumor, and its failure to gain regulatory approval could delay the company's plans to expand its oncology portfolio.
The decision highlights the challenges pharmaceutical companies face in bringing new cancer treatments to market, particularly when clinical data does not meet the rigorous standards set by regulatory bodies.
AstraZeneca may now need to conduct further trials or revise its approach to address the panel's concerns.